Arcturus Therapeutics Holdings Inc. (ARCT) has experienced a substantial pullback in its share price, with the stock currently hovering around $25, representing a steep decline of over 40% from its 52-week high of $45 reached just earlier this month.
This global messenger RNA medicines company is focused on developing vaccines and therapeutics for infectious diseases and rare genetic disorders, leveraging its proprietary LUNAR platform. The lead investigational product is ARCT-810, a systemically delivered mRNA for Ornithine Transcarbamylase (OTC) Deficiency.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com